• Explore /
  • Poster
  • / Safety, tolerability, and preliminary efficacy of TAR-200 in patients with intermediate risk non–muscle-invasive bladder cancer: A phase 1 study.

Safety, tolerability, and preliminary efficacy of TAR-200 in patients with intermediate risk non–muscle-invasive bladder cancer: A phase 1 study.

Abstract Poster

Authors

null

F. Johannes P. van Valenberg

Radboudumc, Department of Urology, Nijmegen, Netherlands

F. Johannes P. van Valenberg , Toine van der Heijden , Christopher Cutie , Sumeet Kaur Bhanvadia , Kirk A. Keegan , Shalaka Hampras , Hussein Sweiti , John Maffeo , Shu Jin , Albert Chau , Don Reynolds , Crysti Iarossi , April Kelley , Xiang Li , Katherine Stromberg , Michiel Sedelaar , Jessica Steenbruggen , Diederik Meindert Somford , Alfred Alfred Witjes

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer and Urothelial Carcinoma

Track

Urothelial Carcinoma,Prostate Cancer - Advanced

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02720367

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 505)

DOI

10.1200/JCO.2023.41.6_suppl.505

Abstract #

505

Poster Bd #

K9

Abstract Disclosures

Similar Posters

First Author: Sunil H. Patel

First Author: Xiao Yang

Poster

2024 ASCO Gastrointestinal Cancers Symposium

A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer.

A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer.

First Author: Yan-Shen Shan

First Author: Hizra Farrukh